Given that insufficient NLRP1 exacerbated eosinophilia and IL-13 levels in the mouse model we studied, it is conceivable that blocking this axis with agents such as IL-4Rα may work more effectively in carriers of the NLRP1 M1184V variant. The gene discussed is IL4R; the disease is Increased total eosinophil count.